Most researchers are obsessed with ligand-receptor interactions, as if biology were just a series of keys finding locks in a vacuum. We’ve mapped the proteome, the metabolome, and the epigenome, but we have almost zero data on interstitial impedance—the physical resistance molecules hit as they move through the extracellular matrix (ECM).

Think about why a perfectly designed small molecule works in a petri dish but fails in a 70-year-old’s femoral tissue. It isn’t just a simple failure of metabolism or bioavailability; it’s molecular gridlock. As we age, the cross-linking of the ECM does more than just make us stiff. It fundamentally alters the diffusion kinetics of the entire organism. We’re treating aging like a software bug, but it’s actually a plumbing failure at the nanoscopic level.

We talk about Crocetin or Butyrate like they’re magic bullets, but we don’t really know what the mean free path of these molecules looks like in aged, fibrotic tissue. If the "interstitial wind" stops blowing, the signal never reaches the metabolic switch. We’re essentially pouring high-octane fuel into an engine where the lines have narrowed to the width of a human hair.

Here’s the honest admission: we’re currently blind to the fluid. We lack the sensors to measure the real-time rheology of the space between cells in a living human. We assume the interstitium is a passive backdrop, a simple saline stage for the real actors. It isn’t. It’s a dynamic, high-viscosity filter that we’re systematically ignoring.

To move past the current plateau, we have to stop looking only at the cells and start looking at the geometry of the gaps between them. We need fluid physicists and mechanical engineers to stop building bridges and start building maps of the human extracellular space. We need funding for in vivo rheology, not just another sequencing run. Until we solve the delivery physics, the most elegant chemistry in the world is just expensive noise.